Management Appointments

Smith & Nephew Plc
09 February 2006


Smith & Nephew senior management appointments

9 February 2006


Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business,
announced today that it has made three new Business Unit President appointments
with immediate effect.

Smith & Nephew's Orthopaedics business has grown strongly in the last five
years, with performance consistently ahead of its markets.  To develop this
business further, we are now identifying two separate business units;
Orthopaedic Reconstruction and Orthopaedic Trauma (including Clinical
Therapies).  This change is at the heart of our strategy to focus our businesses
on the markets and customers that they serve.

Scott Flora, currently Senior Vice-President and General Manager of the
Reconstructive Division, is promoted to President Orthopaedic Reconstruction.
Scott has over 20 years experience in the medical device industry including
working with companies such as Johnson & Johnson.  He joined Smith & Nephew in
1986 as a sales representative and was progressively promoted becoming Senior
Vice-President of Trauma and Clinical Therapies Division in 2003.  In March 2005
he was appointed to his current role.

Mark Augusti is promoted to President Orthopaedic Trauma and Clinical Therapies.
Mark started his career in sales with GE Medical Systems and spent 13 years
there in a number of roles based in the US and Asia.  He joined Smith & Nephew
in April 2003 as Vice President of Global Marketing for the Trauma Division and
was promoted to Senior Vice-President and General Manager Trauma Division in
March 2005.

After 30 years with Smith & Nephew, the last seven years as President of
Advanced Wound Management, Jim Dick will be retiring in the summer of this year.

Joe Woody, currently the Vice President and General Manager of the Clinical
Therapies Division, has been appointed as Jim's successor as President of
Advanced Wound Management.  Joe has 20 years experience in marketing and sales
and worked for Alliance Imaging, Acuson and GE Medical Systems before joining
Smith & Nephew in 2003.  Under his leadership Clinical Therapies has grown
rapidly into a significant business.  Joe will re-locate to the UK to take up
his new role.

Sir Christopher O'Donnell, Chief Executive of Smith & Nephew, commenting on
these appointments today said:

'Smith & Nephew's Orthopaedics business has grown substantially in recent years
with performance consistently ahead of its markets.  As a consequence of
segmenting our Orthopaedics business we are able to promote two highly talented
people to President.  The appointment of Scott Flora and Mark Augusti coincide
with an exciting time for these businesses with excellent opportunities for
continued above market growth.'

'Joe Woody has made a major contribution in leading the excellent growth
achieved by Clinical Therapies.  We look forward to benefiting from his broad
experience in sales and marketing, particularly in the United States, in
accelerating growth in our Advanced Wound Management business.'

Commenting on Jim Dick's retirement, Christopher O'Donnell added: 'Under Jim
Advanced Wound Management has evolved into a global leader with strong market
positions in all major countries of the world.  I would like to thank Jim for
his contribution to the Group over many years.'



Enquiries


Investors
Sir Christopher O'Donnell                 Tel:         [phone]
Smith & Nephew
Chief Executive

Investors / Media
Liz Hewitt                                Tel:         [phone]
Smith & Nephew
Group Director Corporate Affairs



About us



Smith & Nephew is a global medical technology business, specialising in
Orthopaedics, Endoscopy and Advanced Wound Management products.  Smith & Nephew
is a global leader in arthroscopy and advanced wound management and is one of
the fastest growing global orthopaedics companies.



Smith & Nephew is dedicated to helping improve people's lives.  The company
prides itself on the strength of its relationships with its surgeons and
professional healthcare customers, with whom its name is synonymous with high
standards of performance, innovation and trust.  The company has over 8,500
employees and operates in 33 countries around the world generating annual sales
of $2.6 billion.






                      This information is provided by RNS
            The company news service from the London Stock Exchange